Takeda and AC Immune Strike $2.1 Billion Deal for Alzheimer’s Vaccine Development
Takeda Pharmaceutical Company Limited and AC Immune SA have entered into a significant partnership involving ACI-24.060, an experimental active immunotherapy for Alzheimer's disease. The therapy aims to stimulate an immune response to counteract the toxic amyloid beta plaques associated with the disease's progression. Under the terms of the agreement, Takeda has made an upfront payment of $100 million to AC Immune, with the potential for additional milestone payments that could reach approximately $2.1 billion.
The deal grants Takeda an exclusive option to license the global rights for ACI-24.060, which is currently undergoing a phase 1b/2 clinical trial in individuals with prodromal Alzheimer’s disease and adults with Down syndrome. If the option is exercised, Takeda will take on the responsibility for the drug's continued clinical development, regulatory activities, and future commercialization on a worldwide scale. AC Immune stands to receive tiered double-digit royalties on global sales, should the treatment reach the commercial stage.
The collaboration aligns with Takeda's strategic focus on neuroscience and its commitment to addressing challenging neurological conditions such as Alzheimer's disease. Despite fluctuations in financial performance, the agreement reflects both companies' dedication to advancing Alzheimer's disease treatment options.
